Latest Safety News

Page 26 of 205
PYC Therapeutics has secured Safety Review Committee approval to escalate dosing of its investigational drug PYC-001 for Autosomal Dominant Optic Atrophy from single to multiple doses, marking a key step in its clinical development.
Ada Torres
Ada Torres
15 Apr 2026
Scott Technology delivered a solid HY26 with 7% EBITDA growth to $13 million, driven by strong performances in Materials Handling and Mining, offsetting softness in Protein and Appliances. Forward work rose to $177 million, underpinning expectations for a stronger second half despite geopolitical uncertainties.
Victor Sage
Victor Sage
15 Apr 2026
Noxopharm appoints its Chief Scientific Officer Dr Olivier Laczka as CEO, aiming to capitalise on recent clinical successes and expand the Sofra™ technology’s reach in autoimmune and oncology markets.
Ada Torres
Ada Torres
15 Apr 2026
Immutep Limited has won FDA Orphan Drug Designation for its immunotherapy eftilagimod alfa in treating soft tissue sarcoma, opening regulatory incentives and potential market exclusivity. This follows encouraging Phase II data despite recent Phase III trial setbacks.
Ada Torres
Ada Torres
15 Apr 2026
Qoria Limited and Aura have pushed back their merger timeline to July 2026 amid transaction complexities, with Aura providing a A$10 million unsecured working capital facility to support Qoria through the interim period.
Sophie Babbage
Sophie Babbage
15 Apr 2026
Nyrada has secured ethics approval to start its Phase IIa trial of Xolatryp in heart attack patients, with recruitment beginning in April 2026. The biotech also bolsters its cash position to AU$6.74 million and pursues new oncology indications.
Ada Torres
Ada Torres
15 Apr 2026
AVITA Medical’s Cohealyx-I study interim results show a significant acceleration in skin grafting time for full-thickness wounds, reducing mean time to graft from 33.2 to 13.6 days. The ongoing trial’s promising data could reshape wound care protocols.
Ada Torres
Ada Torres
15 Apr 2026
Yancoal Australia is set to acquire an 80% stake in the Kestrel Coal Mine for US$1.85 billion upfront plus up to US$550 million in contingent payments, significantly boosting its metallurgical coal portfolio and production scale in Queensland.
Maxwell Dee
Maxwell Dee
14 Apr 2026
Percheron Therapeutics has closed a $2.2 million entitlement offer to advance its HMBD-002 immuno-oncology candidate towards a phase II trial in 2026, backed by strong shareholder and new investor support.
Ada Torres
Ada Torres
14 Apr 2026
Noxopharm Limited's CEO and Managing Director Dr Gisela Mautner has resigned after four years with the company, including leading a key strategic pivot. The biotech firm plans to announce her successor shortly.
Ada Torres
Ada Torres
14 Apr 2026
Entropy Neurodynamics has dosed its third patient with TRP-8803 in a Binge Eating Disorder trial, achieving a full and controlled psychedelic response that underscores the drug’s potential for precise therapeutic delivery.
Ada Torres
Ada Torres
14 Apr 2026
Bayan Mining and Minerals has locked in a reverse circulation drill rig with Alaska Midnight Sun Drilling for its first-ever drilling at the Desert Star rare earth project in California, targeting up to 1,000 metres from June 2026. The fully permitted program aims to test high-grade surface mineralisation and geophysical targets near the Mountain Pass mine.
Maxwell Dee
Maxwell Dee
14 Apr 2026